Clinical trial
Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's…
NCT00103740 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00103740 |
|---|---|
| Title | Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period |
| Official title | Randomized, Double-Blind, Safety and Efficacy Trial With Intravenous Zoledronic Acid for the Treatment of Paget's Disease of Bone Using Risedronate as a Comparator, Including an Extended Observation Period |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Paget's Disease of Bone |
| Intervention type | Drug |
| Interventions | zoledronic acid, placebo to zoledronic acid, Risedronate, Placebo to risedronate, Calcium and vitamin D supplements |
| Enrollment | 185 |
| Start date | Apr 1, 2002 |
| Primary completion | Dec 1, 2003 |
| Completion | Apr 1, 2011 |
| First posted | Feb 15, 2005 |
| Last update posted | Jun 4, 2012 |
| Countries | Australia, Belgium, Canada, France, Germany, New Zealand, South Africa, Spain, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: